{"id":945319,"date":"2026-03-18T08:09:13","date_gmt":"2026-03-18T12:09:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/"},"modified":"2026-03-18T08:09:13","modified_gmt":"2026-03-18T12:09:13","slug":"akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/","title":{"rendered":"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TAMPA, Fla. and LONDON, March  18, 2026  (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IGExcGM2z0Sx2X7pBGGri6qVu741xH0ccmoV3QqCwOIMFZg559NmVjl9cReqce64ajkKC6l5BgOcp5jhSncuaHBu4bF5wYw0yv814fah7ASaF_Ohx7Jhvqk4h-5qCQpeFuhb4tDBTzt2JFMSLdxZFIiDLp-dL_RuW78e7Wz34YU04hXk5X_vyTeffOSj_t9v\" rel=\"nofollow\" target=\"_blank\">American Association for Cancer Research Annual Meeting 2026<\/a>, being held April 17\u201322, 2026.<\/p>\n<p align=\"justify\">\n        <strong>Details of the poster presentation are as follows:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Title:<\/strong> Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast<br \/><strong>Poster Number:<\/strong> 3179<br \/><strong>Poster Board Number:<\/strong> 14<br \/><strong>Session Category:<\/strong> Experimental and Molecular Therapeutics<br \/><strong>Session Title:<\/strong> Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance<br \/><strong>Date and Time:<\/strong> Monday, April 20, 2026 | 2:00 PM \u2013 5:00 PM PT<br \/><strong>Location:<\/strong> Poster Section 19<\/p>\n<p align=\"justify\">The poster presented at the conference will be available for review on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H0QmLSw5utK8-UrBGFcXHnPJP7c_YOwKvOMpcmmB1ccRdt02CkXZUZ7H3ch55T02EGR_khRZ5EUhB7zZLSUuZEMsAZKKV3fTvaA3V1pQzJAavde3_XHDbEY1MrleGkyk\" rel=\"nofollow\" target=\"_blank\">Posters &amp; Publications<\/a> page on the Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t8XJwxWzQTAcpMrcg59XMSJTIrx_F4nSzZtaM3nd3dnC-zHgxbMF82f0-v2xUlkNhhJSw3T5nIBWwrFkAn2zmA==\" rel=\"nofollow\" target=\"_blank\">website<\/a> on April 20, 2026 after 5:00 PM PT.<\/p>\n<p align=\"justify\">Parties interested in meeting with the Akari team at the conference can direct inquires to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WEooBVhJltxQ6tt2ktodZKRBEEG8GODN4f4jcySzpCZIottVGSjs6hckAHtYi_bxWVFF4joBV5dB0ip5lT5Vkm3VnZZILMueInyiuQD77uM=\" rel=\"nofollow\" target=\"_blank\">info@akaritx.com<\/a>.<\/p>\n<p align=\"justify\">For more information about the American Association for Cancer Research Annual Meeting 2026, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9rKWVC0ZjWC-M-roP8PpEFuiiEjgz3qMTpohcSoA8JPEZFYRZx1iorWJe5PoKrJRBMcPXayiBnxu4du1BKlPi0X-o9ZU5CMs84XbLRxlUGBTUqdoKvI31WXmjokw9nn6\" rel=\"nofollow\" target=\"_blank\">aacr.org<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Akari Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari\u2019s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as K-RAS G12V, BRAF G466V, AR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026\/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari\u2019s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.<\/p>\n<p align=\"justify\">For more information about the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jcU6sgKd6eqQ9WQ_EC5MtY2T86tKnRKjnuWxMm4bFUpnw1XhOrr3oKJ_HdHa6dG78QSceAhBr3IjtYXUgqOKhTZ6EONFdJqN0EAzmo-TK4E=\" rel=\"nofollow\" target=\"_blank\">www.akaritx.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nITia5ejPH0Aaxfph0IxxsEt-SFX3enV0igW75p5w-x0ASN2BwTv3wK1DDINJyDPOkPrHyLpjTZ6ftRLeynTWw==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cDprqp0peNly6fumZZ7OcaO_Frl0ijGFr6v779DQeuc10BO0mGANzErmetwu4k0eENlL2uvxoez0hM5xdNJ_GG5fgkcYOrR9gwxOHCnfcR4=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><\/p>\n<p>This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that\u00a0involve\u00a0risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cfuture,\u201d \u201copportunity\u201d \u201cwill likely result,\u201d \u201ctarget,\u201d variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other\u00a0diseases, and\u00a0ultimately bring therapies to patients. These statements are based on the Company\u2019s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific.\u00a0A number of\u00a0important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company\u2019s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and\/or development of the Company\u2019s programs or product candidates; risks related to any loss of the Company\u2019s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company\u2019s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and\/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and\/or its collaborators or licensees may be replicated in other studies and\/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company\u2019s product candidates; risks related to competition for the Company\u2019s product candidates; and the Company\u2019s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should\u00a0be considered to be\u00a0a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the SEC, copies of which may be obtained from the SEC\u2019s website at www.sec.gov. The Company assumes no, and hereby disclaims\u00a0any, obligation to update the forward-looking statements contained in this press release except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact <\/strong>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC <br \/>Jenene Thomas <br \/>908-824-0775 <br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AktbuGVIsoVxMRljzJNfCtqo5okWB5qiyxrPtYgeOHUboFUWR1JH3cnPXYqFMQDh0IMDjRz4J02kGGevJ1o6SA==\" rel=\"nofollow\" target=\"_blank\">AKTX@jtcir.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzQ2MGIyOTEtN2M5NC00OTRiLWE0NDQtZWM1NjUwOWQzMDBiLTEwMzE4MzUtMjAyNi0wMy0xOC1lbg==\/tiny\/Akari-Therapeutics-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17\u201322, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breastPoster Number: 3179Poster Board Number: 14Session Category: Experimental and Molecular TherapeuticsSession Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic ResistanceDate and Time: Monday, April 20, 2026 | 2:00 PM \u2013 5:00 PM PTLocation: Poster Section 19 The poster presented &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945319","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17\u201322, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breastPoster Number: 3179Poster Board Number: 14Session Category: Experimental and Molecular TherapeuticsSession Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic ResistanceDate and Time: Monday, April 20, 2026 | 2:00 PM \u2013 5:00 PM PTLocation: Poster Section 19 The poster presented &hellip; Continue reading &quot;Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T12:09:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026\",\"datePublished\":\"2026-03-18T12:09:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/\"},\"wordCount\":1066,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/\",\"name\":\"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=\",\"datePublished\":\"2026-03-18T12:09:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/","og_locale":"en_US","og_type":"article","og_title":"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - Market Newsdesk","og_description":"TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17\u201322, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breastPoster Number: 3179Poster Board Number: 14Session Category: Experimental and Molecular TherapeuticsSession Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic ResistanceDate and Time: Monday, April 20, 2026 | 2:00 PM \u2013 5:00 PM PTLocation: Poster Section 19 The poster presented &hellip; Continue reading \"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T12:09:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026","datePublished":"2026-03-18T12:09:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/"},"wordCount":1066,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/","name":"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=","datePublished":"2026-03-18T12:09:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDExOSM3NDkxMDUxIzIwMjAyNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945319"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945319\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}